Nov 29, 2022 / 02:30PM GMT
Ted Tenthoff - Piper Sandler - Analyst
Good morning, everyone. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler, and thank you for joining us for this year's in-person Healthcare Conference.
Before I begin, I am required to point out certain disclosures regarding the relationship between Piper Sandler and Bicycle, our next presenting company, that are located at the back of the room and also at the registration desk. So Bicycle is developing a novel class of bi-cyclic peptides, aptly called Bicycles, to treat cancer and a range of other diseases. The company is in the clinic with multiple Bicycle Toxin Conjugates or BTCs. And now also tumor-targeted immune cell agonists or TICAs for immuno-oncology.
The company has partnerships with Genentech, Ionis, Oxurion, AstraZeneca. And here with us today is Chief Scientific Officer, Nick Keen; Chief Medical Officer, Dominic Smethurst; and also CFO, Lee Kalowski. Guys, thanks for being with us.
Questions and Answers:
Ted Tenthoff - Piper Sandler - AnalystSo Nick, maybe you
Trustpilot
